SYNAPDX
SynapDx's mission is to provide laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. Autism Spectrum Disorders are currently estimated to affect 1 in 110 children in the United States according to the Centers for Disease Control. SynapDx was founded by Stanley Lapidus and closed a Series A round of venture funding in May 2010 from North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners. SynapDx's corporate headquarters is located in Lexington, Massachusetts.
SYNAPDX
Industry:
Health Care Health Diagnostics Medical Device
Founded:
2010-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.synapdx.com
Total Employee:
11+
Status:
Closed
Contact:
+1 781 250 2844
Email Addresses:
[email protected]
Total Funding:
32.4 M USD
Technology used in webpage:
Viewport Meta SPF Domain Not Resolving SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Font API Google Analytics HSTS Content Delivery Network
Similar Organizations
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Lia
Lia Diagnostics develops flush-able and eco-friendly pregnancy test.
LucyDx
LucyDX is on a mission to prevent blindness in diabetics through early detection.
NinePoint Medical
NinePoint Medical is a transformational medical device company developing innovative, real-time, in vivo pathology devices.
Seno Medical Instruments
Seno Medical is commercialization efforts in opto-acoustic imaging of breast cancer.
SomaLogic
SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.
Current Advisors List
Current Employees Featured
Founder
Investors List
LabCorp
LabCorp investment in Venture Round - SynapDx
Google Ventures
Google Ventures investment in Venture Round - SynapDx
The Kraft Group
The Kraft Group investment in Venture Round - SynapDx
The Kraft Group
The Kraft Group investment in Venture Round - SynapDx
LabCorp
LabCorp investment in Series C - SynapDx
General Catalyst
General Catalyst investment in Series B - SynapDx
North Bridge Venture Partners & Growth Equity
North Bridge Venture Partners & Growth Equity investment in Series B - SynapDx
Bain Capital Ventures
Bain Capital Ventures investment in Series A - SynapDx
General Catalyst
General Catalyst investment in Series A - SynapDx
North Bridge Venture Partners & Growth Equity
North Bridge Venture Partners & Growth Equity investment in Series A - SynapDx
Official Site Inspections
http://www.synapdx.com
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 76.223.67.189
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "SynapDx"
About SynapsDX | Synaps DX
In addition of being appointed Dean ad interim, for his services to the research and educational mission of UTMB, over the years Dr. Taglialatela has received numerous awards, including, in …See details»
Synaps Dx - Crunchbase Company Profile & Funding
Organization. Synaps Dx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Synaps Dx is a privately held company focused on the …See details»
SYNAPS Dx - An Alzheimer's Diagnostic company
Synaps Dx is dedicated to transforming the diagnosis of Alzheimer’s disease (AD). Operating a CLIA-certified laboratory, we offer DISCERNâ„¢, the first commercially available test to accurately ...See details»
SYNAPS Dx Company Profile 2024: Valuation, Funding & Investors
SYNAPS Dx General Information Description. Developer of Alzheimer's disease diagnostic tool designed to commercialize the biomarker technology. The company research develops and …See details»
Benefits of the DISCERNâ„¢ Test in Clinical Practice
[email protected] +1 (301) 294-7180. This test was developed, and its performance characteristics determined by NeuroDiagnostics Inc, dba Synaps Dx. It has not been cleared …See details»
SYNAPS Dx Announces Prestigious Scientific Advisory Board to …
ROCKVILLE, Md., January 17, 2024--SDx Announces Prestigious Scientific Advisory Board to Guide Strategy and Commercialization of DISCERNâ„¢ Test for Diagnosis of Alzheimer's DiseaseSee details»
SYNAPS Dx Announces Prestigious Scientific Advisory …
Jan 17, 2024 Contact: [email protected]. Contacts. Media: Caroline Chambers CPR Communications [email protected] 201.641.1911 x 21 Release Summary.See details»
Spotlight Interview: Frank Amato, President and CEO, …
Oct 19, 2021 Medical Travel & Digital Health News (MTDHN): How did both of you get involved with SYNAPS Dx? Dr. Daniel Alkon (DA): I spent much of my career as an academician, program director and laboratory chief at the …See details»
Synaps Dx Launches Digital Cognitive Screening and Alzheimer’s …
Nov 6, 2024 To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and …See details»
SYNAPS Dx Opens High-Tech Laboratory Supporting Research ...
Aug 9, 2022 SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is …See details»
SYNAPS Dx Announces Investment by Semler Scientific: Advances ...
Mar 2, 2022 Contact: [email protected]. Contacts. Media: Brittany Tedesco CPR Communications [email protected] 201.641.1911 x 14 Release Summary.See details»
SYNAPS Dx Opens High-Tech Laboratory Supporting Research ...
Aug 9, 2022 Contact: [email protected]. Contacts. Media: Caroline Chambers CPR Communications [email protected] 201.641.1911 x 21 Release Summary.See details»
SYNAPS Dx Completes $10 Million Series A Investment, …
Oct 12, 2021 ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for …See details»
Science - SYNAPS Dx
[email protected] +1 (301) 294-7180. This test was developed, and its performance characteristics determined by NeuroDiagnostics Inc, dba Synaps Dx. It has not been cleared …See details»
SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN
Sep 5, 2023 ROCKVILLE, Md.--(BUSINESS WIRE)-- SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for …See details»
SYNAPS Dx Names Leading Healthcare Executives and Innovators …
Dec 15, 2021 Contact: [email protected]. Contacts. Media: Brittany Tedesco CPR Communications [email protected] 201.641.1911 x 14 Release Summary.See details»
SYNAPS Dx DISCERN Provides First-to-Market Definitive …
Jan 31, 2022 Contact: [email protected]. Contacts. Media: Brittany Tedesco CPR Communications [email protected] 201.641.1911 x 14 Release Summary.See details»
News - SYNAPS Dx
[email protected] +1 (301) 294-7180. This test was developed, and its performance characteristics determined by NeuroDiagnostics Inc, dba Synaps Dx. It has not been cleared …See details»
SYNAPS Dx Selects FrontRunner Health Care - Business Wire
Oct 11, 2022 ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for …See details»